Achoo! New help for kids suffering colds? Canadian researchers launch rare trial

October 21, 2010

Three Canadian research teams are trying to determine if a novel Canadian medicine approved by Health Canada for adults can help parents deal with the hacking coughs and runny noses their children suffer. Five hundred children will be recruited for a landmark trial, which follows a positive safety trial that was published in Pediatrics - the official journal of the American Academy of Pediatrics.

The trial comes at a time of considerable controversy involving pediatric cold and flu medicines. Critics argue, and the FDA agrees, that most of the hundreds of OTC cold treatments for children currently on pharmacy shelves have not gone through clinical safety, efficacy and dosing trials. In 2007, an FDA summary report concluded that for the 50 year period ending in 2004, there were only 11 published trials of OTC cough and cold products for children and none demonstrated efficacy. The federal agency is attempting to change that by offering the industry extended patents when they conduct pediatric research. A major gap remains. Today's announcement of a multi-centre randomized, double-blind placebo-controlled trial is one of the very few trials ever conducted for any cold and flu over the counter medicine for children.

Children get an estimated 6 to 10 colds a year and as a result miss millions of school days. Studies show that 10% of children are given cough and cold medicines each week in America. The Centre for Disease Control and Prevention (CDC) says that every year more than 7,000 children under 12 years of age are treated in U.S. emergency rooms for adverse reactions to pediatric cough and cold medicines.

Researchers in Edmonton, Halifax and Saint John, New Brunswick will focus on a patented extract of North American ginseng called COLD FX® which is currently the # 1 selling adult cold and flu medicine in Canada. It's backed by eleven clinical trials, most of them conducted at 8 universities in both Canada and the U.S. The FDA has cleared its sale in the U.S. for adults under new dietary ingredient (NDI) legislation.

Recruitment of 500 children, three to 11 years of age, began today. Researchers estimate that approximately 60% of the children in the study will develop an infection and then be eligible to enter the clinical trial. Children will be encouraged to get their annual flu shot. Each child will be randomized to take either a special children's formulation of COLD-FX or a placebo for three days. They will be closely monitored for 14 days.

Dr. Jacqueline Shan, who along with a team of 24 other scientists discovered COLD-FX, says, "We hope this multi-centre trial will be viewed as timely and beneficial research in an area where there are few options for parents and a clear need for safe and effective clinically proven products to treat cold and flu in children."

CV Technologies Inc.

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to